Bryan C Fuchs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3424614/publications.pdf

Version: 2024-02-01

91712 87723 5,064 84 38 69 citations h-index g-index papers 85 85 85 7985 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrolysis Function and Promotes Collagen Resolution in Liver. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1483-1509.	2.3	9
2	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	0.6	17
3	Abstract 255: Peroxidasin deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. Cancer Research, 2022, 82, 255-255.	0.4	O
4	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight, 2022, 7, .	2.3	4
5	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut, 2021, 70, 157-169.	6.1	57
6	Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Scientific Reports, 2021, 11, 6105.	1.6	4
7	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	2.2	31
8	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	5 . 8	21
9	Molecular Magnetic Resonance Imaging of Liver Fibrosis and Fibrogenesis Is Not Altered by Inflammation. Investigative Radiology, 2021, 56, 244-251.	3.5	6
10	Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Molecular Therapy - Oncolytics, 2021, 23, 547-559.	2.0	5
11	Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. Investigative Radiology, 2020, 55, 209-216.	3.5	15
12	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine, 2020, 9, 3817.	1.0	27
13	Collagen-targeted molecular imaging in diffuse liver diseases. Abdominal Radiology, 2020, 45, 3545-3556.	1.0	7
14	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. Journal of Hepatology, 2020, 73, S28-S29.	1.8	0
15	Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Science Translational Medicine, 2020, 12, .	5 . 8	71
16	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology, 2020, 296, 67-75.	3.6	22
17	Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. Journal of Hepatology, 2020, 73, 896-905.	1.8	119
18	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. American Journal of Surgery, 2020, 220, 1579-1585.	0.9	12

#	Article	IF	CITATIONS
19	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Clinical Cancer Research, 2020, 26, 5007-5018.	3.2	29
20	Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 497-508.	0.7	24
21	Serum Angiopoietinâ€⊋ Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	3. 6	26
22	Exploring donor demographics effects on hepatocyte yield and viability: Results of whole human liver isolation from one center. Technology, 2019, 07, 1-11.	1.4	2
23	THU-084-A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of non-alcoholic steatohepatitis cirrhosis. Journal of Hepatology, 2019, 70, e196-e197.	1.8	0
24	THU-093-The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of non-alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, e201-e202.	1.8	3
25	HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology, 2019, 156, 2313-2329.e7.	0.6	184
26	⁶⁸ Ga-NODAGA-Indole: An Allysine-Reactive Positron Emission Tomography Probe for Molecular Imaging of Pulmonary Fibrogenesis. Journal of the American Chemical Society, 2019, 141, 5593-5596.	6.6	23
27	The farnesoid X receptor agonist EDPâ€305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction. FASEB Journal, 2019, 33, 7103-7112.	0.2	29
28	Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex. Journal of the American Chemical Society, 2019, 141, 5916-5925.	6.6	96
29	Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. Investigative Radiology, 2019, 54, 697-703.	3.5	45
30	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metabolism, 2019, 29, 174-182.e5.	7.2	246
31	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. Journal of Gastrointestinal Surgery, 2019, 23, 101-111.	0.9	30
32	Molecular imaging of fibrosis: recent advances and future directions. Journal of Clinical Investigation, 2019, 129, 24-33.	3.9	86
33	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer, 2018, 124, 3084-3104.	2.0	42
34	In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Experimental and Molecular Medicine, 2018, 50, e419-e419.	3.2	37
35	Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet―nduced mouse model of nonalcoholic steatohepatitis. Hepatology Communications, 2018, 2, 529-545.	2.0	43
36	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology, 2018, 68, 1125-1139.	3.6	74

#	Article	IF	CITATIONS
37	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	1.7	12
38	Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure–Activity Relationships and Lead Candidate Evaluation. Journal of Medicinal Chemistry, 2018, 61, 8811-8824.	2.9	72
39	Collagen targeted MRI accurately measures the desmoplastic response to folfirinox treatment in a murine model of pancreatic cancer. Hpb, 2018, 20, S23-S24.	0.1	1
40	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
41	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDPâ€305, a novel farnesoid X receptor agonist. Hepatology Communications, 2018, 2, 821-835.	2.0	46
42	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	60
43	CM-101: Type I Collagen–targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology, 2018, 287, 581-589.	3.6	43
44	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 2017, 7, 42563.	1.6	29
45	The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Molecular and Cellular Oncology, 2017, 4, e1311827.	0.3	22
46	Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. Journal of Nuclear Medicine, 2017, 58, 1991-1996.	2.8	50
47	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Scientific Reports, 2017, 7, 44867.	1.6	22
48	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Letters, 2017, 409, 9-19.	3.2	48
49	Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clinical and Translational Gastroenterology, 2017, 8, e101.	1.3	124
50	Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. Hepatology, 2017, 65, 1015-1025.	3.6	43
51	Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. JCI Insight, 2017, 2, .	2.3	57
52	STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surgery and Nutrition, 2016, 5, 201-203.	0.7	23
53	Disease Biomarkers in Gastrointestinal Malignancies. Disease Markers, 2016, 2016, 1-3.	0.6	2
54	Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer, 2016, 122, 1216-1227.	2.0	65

#	Article	IF	CITATIONS
55	Impact of <i><scp>EGF</scp></i> , <i><scp>IL</scp>28B</i> , and <i><scp>PNPLA</scp>3</i> polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clinical Transplantation, 2016, 30, 452-460.	0.8	2
56	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	7.7	172
57	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Scientific Reports, 2016, 6, 39342.	1.6	77
58	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials, 2016, 93, 71-82.	5.7	35
59	Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. International Journal of Cancer, 2016, 138, 1494-1505.	2.3	29
60	T2 relaxation time is related to liver fibrosis severity. Quantitative Imaging in Medicine and Surgery, 2016, 6, 103-114.	1.1	54
61	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Journal of Surgical Oncology, 2015, 112, 622-628.	0.8	14
62	Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer. Annals of Thoracic Surgery, 2015, 100, 414-421.	0.7	25
63	3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. Journal of Hepatology, 2015, 63, 689-696.	1.8	57
64	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Current Pathobiology Reports, 2014, 2, 245-256.	1.6	30
65	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology, 2014, 59, 1577-1590.	3.6	290
66	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology, 2014, 61, S79-S90.	1.8	181
67	Epithelial to Mesenchymal Transition is Associated with Shorter Disease-Free Survival in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2014, 21, 3882-3890.	0.7	61
68	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. PLoS ONE, 2014, 9, e114747.	1.1	11
69	Molecular Magnetic Resonance Imaging of Pulmonary Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 1120-1126.	1.4	89
70	Molecular MRI of collagen to diagnose and stage liver fibrosis. Journal of Hepatology, 2013, 59, 992-998.	1.8	128
71	Epithelial growth factor receptor inhibition effectively inhibits liver fibrosis and hepatocellular carcinoma. Journal of the American College of Surgeons, 2013, 217, S20.	0.2	0
72	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	1.0	18

#	Article	IF	CITATIONS
73	Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. Cancer Investigation, 2012, 30, 243-250.	0.6	19
74	Genomic risk of hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 729-730.	1.8	15
75	Molecular MR imaging of liver fibrosis: A feasibility study using rat and mouse models. Journal of Hepatology, 2012, 57, 549-555.	1.8	97
76	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets, 2012, 12, 1129-59.	0.8	55
77	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. Gastroenterology, 2011, 141, 141-149.	0.6	133
78	A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome. Clinical Cancer Research, 2008, 14, 3216-3222.	3.2	80
79	Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells. Cancer Research, 2008, 68, 2391-2399.	0.4	287
80	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. JAMA - Journal of the American Medical Association, 2008, 299, 53-60.	3.8	183
81	Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis. Cancer Research, 2007, 67, 3295-3300.	0.4	35
82	Stressing Out Over Survival: Glutamine as an Apoptotic Modulator. Journal of Surgical Research, 2006, 131, 26-40.	0.8	91
83	Type I Diabetes Affects Skeletal Muscle Glutamine Uptake in a Fiber-Specific Manner. Experimental Biology and Medicine, 2005, 230, 606-611.	1.1	8
84	Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?. Seminars in Cancer Biology, 2005, 15, 254-266.	4.3	608